Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.04
-0.03 (-0.49%)
Mar 5, 2026, 4:00 PM EST - Market closed
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Xeris Biopharma Holdings stock have an average target of 10.43, with a low estimate of 8.00 and a high estimate of 18. The average target predicts an increase of 72.68% from the current stock price of 6.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +65.56% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +65.56% | Jan 9, 2026 |
| Barclays | Barclays | Buy Initiates $9 | Buy | Initiates | $9 | +49.01% | Dec 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 | Buy | Maintains | $18 | +198.01% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +65.56% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
375.46M
from 291.85M
Increased by 28.65%
Revenue Next Year
444.27M
from 375.46M
Increased by 18.33%
EPS This Year
0.19
from 0.00
Increased by 5,672.68%
EPS Next Year
0.36
from 0.19
Increased by 96.14%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 453.9M | 526.2M | |||
| Avg | 375.5M | 444.3M | |||
| Low | 331.1M | 382.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 55.5% | 40.1% | |||
| Avg | 28.7% | 18.3% | |||
| Low | 13.5% | 1.9% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 0.43 | 0.64 |
| Avg | 0.19 | 0.36 |
| Low | -0.03 | 0.11 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | 13,323.8% | 246.0% |
| Avg | 5,672.7% | 96.1% |
| Low | - | -41.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.